Skip to main content
    S

    Spyre Therapeutics Inc. (SYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $99.37
    -4.63 (-4.45%)

    Market Cap: $9.88B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Spyre Therapeutics Inc. (SYRE) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Spyre Therapeutics (SYRE) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Spyre Therapeutics reported EPS of -$0.94, below the -$0.79 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    47%(17/36)
    Avg Surprise
    -11.64%

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.93
    Range-$1.93 - -$0.62
    17 analysts
    Revenue Consensus
    N/A
    RangeN/A
    12 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.92
    Range-$1.10 - -$0.67
    4 analysts
    EPS Revisions
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.79-17.2%
    60d ago-$0.84-10.3%
    30d ago-$0.84-10.3%
    7d ago-$0.82-12.2%
    Current-$0.92
    Revenue Consensus
    N/A
    RangeN/A
    6 analysts

    Next Report

    SYRE has an expected report date of Feb 17, 2027.

    Earnings History

    Of the 36 quarters below that had an estimate, SYRE beat 17 and missed 19. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 419.23% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.94-$0.79-$1.53 - -$0.67-18.99%MissN/A130 up, 1 downNov 3, 2026N/A
    Jun 30, 2026-$0.36-$0.71-$1.00 - -$0.49+49.30%BeatN/A130 up, 2 downAug 4, 2026N/A
    Mar 31, 2026-$0.74-$0.64-$0.81 - -$0.53-14.84%MissN/A125 up, 3 downMay 5, 2026N/A
    Dec 31, 2025-$0.74-$0.80-$1.91 - -$0.14+7.50%BeatN/A127 up, 3 downFeb 19, 2026$90.49M
    Sep 30, 2025-$0.15-$0.74-$0.99 - -$0.56+79.73%BeatN/A104 up, 3 downNov 4, 2025N/A
    Jun 30, 2025-$0.49-$0.71-$0.83 - -$0.62+30.99%BeatN/A96 up, 0 downAug 5, 2025N/A
    Mar 31, 2025-$0.60-$0.84-$0.97 - -$0.71+28.57%BeatN/A7N/AMay 8, 2025N/A
    Dec 31, 2024-$0.81-$0.94-$1.14 - -$0.61+14.22%BeatN/A71 up, 0 downFeb 27, 2025N/A
    Sep 30, 2024-$1.36-$0.86-$1.05 - -$0.45-58.14%MissN/A90 up, 0 downNov 7, 2024N/A
    Jun 30, 2024-$0.86-$0.91-$1.21 - -$0.52+5.49%BeatN/A70 up, 0 downAug 7, 2024N/A
    Mar 31, 2024-$1.20-$1.08N/A-11.11%MissN/A40 up, 0 downMay 9, 2024N/A
    Dec 31, 2023-$4.05-$0.78-$1.15 - -$0.20-419.23%MissN/A71 up, 0 downFeb 29, 2024$1.04M
    Sep 30, 2023-$9.34-$0.84N/AN/AN/AN/AN/AN/ANov 9, 2023N/A
    Jun 30, 2023-$56.75-$3.50N/AN/AN/AN/AN/AN/AAug 11, 2023$688000
    Mar 31, 2023-$5.00-$4.37N/A-14.42%MissN/AN/AN/AMay 11, 2023$198000
    Dec 31, 2022-$5.00-$5.71N/A+12.40%BeatN/AN/AN/AMar 30, 2023$168000
    Sep 30, 2022-$4.75-$5.87N/A+19.08%BeatN/AN/AN/ADec 29, 2022$174000
    Jun 30, 2022-$6.75-$7.75N/A+12.90%BeatN/AN/AN/ASep 28, 2022$625000
    Mar 31, 2022-$9.25-$8.54N/A-8.38%MissN/AN/AN/AJun 28, 2022$1.36M
    Dec 31, 2021-$7.75-$7.63N/A-1.57%MissN/AN/AN/AMar 29, 2022$3.64M
    Sep 30, 2021-$7.75-$7.34N/A-5.59%MissN/AN/AN/ADec 29, 2021$1.40M
    Jun 30, 2021-$2.50-$4.30N/A+41.86%BeatN/AN/AN/ASep 28, 2021$13.70M
    Mar 31, 2021-$7.00-$3.49N/A-100.57%MissN/AN/AN/AJun 28, 2021N/A
    Dec 31, 2020-$8.75-$8.57N/A-2.07%MissN/AN/AN/AMar 31, 2021N/A
    Sep 30, 2020-$7.25-$9.97N/A+27.28%BeatN/AN/AN/ANov 5, 2020N/A
    Jun 30, 2020-$10.00-$10.76N/A+7.06%BeatN/AN/AN/AAug 10, 2020N/A
    Mar 31, 2020-$14.25-$16.41N/A+13.16%BeatN/AN/AN/AMay 7, 2020N/A
    Dec 31, 2019-$16.25-$16.75N/A+2.99%BeatN/AN/AN/AFeb 24, 2020N/A
    Sep 30, 2019-$16.50-$13.31N/A-23.97%MissN/AN/AN/ADec 29, 2019N/A
    Jun 30, 2019-$13.75-$12.08N/A-13.82%MissN/AN/AN/AAug 6, 2019N/A
    Mar 31, 2019-$14.75-$13.80N/A-6.88%MissN/AN/AN/AMay 7, 2019N/A
    Dec 31, 2018-$15.50-$0.37N/AN/AN/AN/AN/AN/AMar 31, 2019N/A
    Sep 30, 2018-$13.50-$10.80N/A-25.00%MissN/AN/AN/ADec 29, 2018N/A
    Jun 30, 2018-$11.50-$8.62N/A-33.41%MissN/AN/AN/AAug 9, 2018$2.38M
    Mar 31, 2018-$12.25-$11.51N/A-6.43%MissN/AN/AN/AMay 8, 2018$1.51M
    Dec 31, 2017-$9.75-$0.53N/AN/AN/AN/AN/AN/AMar 31, 2018$1.48M
    Sep 30, 2017-$12.00-$13.77N/A+12.85%BeatN/AN/AN/ADec 29, 2017$1.26M
    Jun 30, 2017-$11.75-$12.00N/A+2.08%BeatN/AN/AN/AAug 9, 2017$1.48M
    Mar 31, 2017-$11.75-$11.70N/A-0.43%MissN/AN/AN/AMay 9, 2017$982000
    Dec 31, 2016-$0.56-$0.46N/A-21.74%MissN/AN/AN/AMar 31, 2017$1.25M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.98, after -$4.23 the year before. It was -$32.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.98N/A
    Dec 31, 2024-$4.23N/A
    Dec 31, 2023-$75.14N/A
    Dec 31, 2022-$25.75N/A
    Dec 31, 2021-$25.00N/A
    Dec 31, 2020-$40.25N/A
    Dec 31, 2019-$61.25N/A
    Dec 31, 2018-$52.75N/A
    Dec 31, 2017-$45.25N/A
    Dec 31, 2016-$32.61N/A

    Frequently Asked Questions About SYRE

    When is Spyre Therapeutics's next earnings date?

    Spyre Therapeutics's next earnings report is expected for Feb 17, 2027.

    Did SYRE beat earnings estimates last quarter?

    No. Spyre Therapeutics reported EPS of -$0.94 for the quarter ended Sep 30, 2026, below the -$0.79 estimate by 18.99%.

    What EPS do analysts expect from SYRE next quarter?

    The consensus EPS estimate for Spyre Therapeutics for the quarter ending Dec 31, 2026 is -$0.93 from 17 analysts, with estimates from -$1.93 to -$0.62.

    How often does SYRE beat earnings estimates?

    Spyre Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +22.06%.